Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the results of the first six months and second quarter ending June 30, 2023 and provided a corporate update.
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the results of the first six months and second quarter ending June 30, 2023 and provided a corporate update.